The mechanisms by which chemically functionalized carbon nanotubes flow in blood and are excreted through the kidneys illustrate the unconventional behaviour of these fibrillar nanostructures, and the opportunities they offer as components for the design of advanced delivery vehicles.
References
Ruggiero, A. et al. Proc. Natl Acad. Sci. USA 107, 12369–12374 (2010).
Kostarelos, K. et al. Nature Nanotech. 2, 108–113 (2007).
Haraldsson, B., Nystrom, J. & Deen, W. M. Physiol. Rev. 88, 451–487 (2008).
Singh, R. et al. Proc. Natl Acad. Sci. USA 103, 3357–3362 (2006).
Lacerda, L. et al. Adv. Mater. 20, 225–230 (2008).
Lacerda, L. et al. Small 4, 1130–1132 (2008).
Liu, Z., Tabakman, S., Welsher, K. & Dai, H. Nano. Res. 2, 85–120 (2009).
Deng, X. et al. Carbon 45, 1419–1424 (2007).
Cedervall, T. et al. Proc. Natl Acad. Sci. USA 104, 2050–2055 (2007).
Kostarelos, K. Nature Biotechnol. 26, 774–776 (2008).
Geng, Y. et al. Nature Nanotech. 2, 249–255 (2007).
Park, J. H. et al. Small 5, 694–700 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kostarelos, K. Fibrillar pharmacology. Nature Mater 9, 793–795 (2010). https://doi.org/10.1038/nmat2871
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmat2871
- Springer Nature Limited
This article is cited by
-
Structural and molecular properties of complexes of biomolecules and metal–organic frameworks: dispersion-corrected DFT treatment
Journal of Molecular Modeling (2022)
-
Fibrillar pharmacology of functionalized nanocellulose
Scientific Reports (2021)
-
Deconvoluting hepatic processing of carbon nanotubes
Nature Communications (2016)
-
Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery
Nature Nanotechnology (2013)